Cuorips, a spinout from Osaka University, has sold an option right for the commercialisation of a treatment for severe heart failure to Daiichi Sankyo in return for an undisclosed sum.
Cuorips, a Japan-based cardiac therapy developer spun out from Osaka University, has secured an undisclosed amount from pharmaceutical firm Daiichi Sankyo.
The investment was made as part of an agreement that gives the corporate an option right for the worldwide commercialisation of Cuorip’s technology, called iPS-derived cardiomyocyte sheet, a cell therapy for patients suffering from severe heart failure.
The treatment uses induced pluripotent stem (iPS) cells, which can be generated directly from a donor’s mature cells and differentiated into any…
